JNM (December 2016): Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions
JNM (December 2016): Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions

JNM (December 2016) Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions

JNM, December 2016, Volume 57, Number 12

 

Member Fee: Free
Non-Member Fee: $15.00

Release Date: December 1, 2016
Expiration Date: December 31, 2019


Author

 

Christophe M. Deroose1, Elif Hindié2,3, Electron Kebebew4, Bernard Goichot5, Karel Pacak6, David Taïeb7–9, and Alessio Imperiale10,11

1Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium; 2Nuclear Medicine, Haut-Lévêque Hospital, University of Bordeaux, France; 3LabEx TRAIL, University of Bordeaux, France; 4Endocrine Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland; 5Internal Medicine, Strasbourg University Hospitals, Strasbourg, France; 6Section on Medical Neuroendocrinology, Eunice Kennedy Shriver NICHD, NIH, Bethesda, Maryland; 7Nuclear Medicine, La Timone University Hospital, Aix-Marseille University, Marseille, France; 8European Center for Research in Medical Imaging, Marseille, France; 9INSERM UMR1068, Marseille, France; 10Biophysics and Nuclear Medicine, Strasbourg University Hospitals, Strasbourg, France; and 11ICube, UMR 7357, University of Strasbourg/CNRS and FMTS, Faculty of Medicine, University of Strasbourg, Strasbourg, France



Financial Disclosure

 

Dr.Dr. Deroose is a consultant/advisor for Sirtex and Ipsen, is a meeting participant/lecturer for Bayer, and is involved in a scienti?c study/ trial for Advanced Accelerator Applications (AAA). AAA (68Ga-DOTATATE, 177Lu-DOTATATE, 18F-DOPA, 18F-FDG) Sirtex (selective internal radiotherapy spheres), Ipsen (Lanreotide, radiolabeled SSTR antagonists) produce diagnostic and therapeutic agents described in this article.

In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the author has indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.

 

 

Target Audience

This article contains information of value to physicians in nuclear medicine, radiologists as well as to nuclear medicine technologists and pharmacists.


Objectives 

At the completion of this activity, the participant should be able to:

1. Summarize the main clinical features of gastroenteropancreatic neuroendocrine tumors;
2. Describe the speci?c mechanisms of uptake of radiotracers and identify the relation of imaging phenotype with site of origin and tumor grade; and
3. Recommend the best imaging modalities across the different tumor subtypes for imaging and for selecting candidates for peptide receptor radionuclide therapy

Continuing Education Credit Information

ACPE (Pharmacists)
The Society for Nuclear Medicine and Molecular Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been designated as knowledge-based CPE. Total available credit for pharmacists is 1.0 hours or 0.10 CEUs. To receive CE credit, learners must achieve a score of 80% on the post-course assessment and complete the evaluation. You will have no more than 3 attempts to successfully complete the post-test. ACPE UPN:
0210-0000-16-060-H04-P.

VOICE (Technologists)
The SNMMI, through its Verification of Involvement in Continuing Education (VOICE) program, has approved this journal article for a maximum of 1.0 continuing education hours (CEHs). VOICE-approved credit is recognized by most licensure states and by the NMTCB and ARRT as Category A+ credit. In order to receive CE credit, you must first complete the activity content. When completed, take the post-test assessment.  You must obtain a score of 80% to receive the CE credit.  You will have no more than 3 attempts to successfully complete the post-test. California Scope: 1.0 Imaging (I).


Minimum system requirements

Supported Operating Systems: Windows (8/7/Vista/XP) or Mac OS X

Supported Internet Browsers: Windows OS Users:
- Microsoft Internet Explorer (version 8 or higher)
- Google Chrome (latest version)
- Mozilla Firefox (latest version)

Supported Internet Browsers: Mac OS X Users:
- Apple Safari (version 4 or higher)
- Google Chrome (latest version)
- Mozilla Firefox (latest version)

Internet Browser Settings:
- Pop-Up Blocker should be disabled
- Java Script should be enabled
- Java should be enabled
- Cookies should be enabled

Plug-ins:
- Adobe Flash Player (http://get.adobe.com/flashplayer/)
- Adobe Acrobat Reader (http://get.adobe.com/reader/)

Hardware Requirements:
- Computer:  1 GHz with 500 MB RAM or better
- Internet Connection:  A broadband connection (DSL, Cable, etc.)
- Sound:  Speakers or headset to hear audio
- Display:  A display screen area of 800 x 600 pixels or higher

Policy on Privacy and Confidentiality: http://www.snmmi.org/index.cfm?PageID=926

For questions please contact the Education Department at Education@snmmi.org 703-708-9000.

© 2016 SNMMI. All rights reserved.   


Type:     Internet Activity (Enduring Material)
1387 Registered Users